Business Wire

NIELSENIQ

9.2.2021 10:02:07 CET | Business Wire | Press release

Share
NielsenIQ Connect Partner Network Expands Globally into Asia and Europe, Strengthening the Largest Open Ecosystem of Tech-driven Partners For Streamlining Data For The CPG Industry

The NielsenIQ Connect Partner Network (CPN) has expanded its business globally into Asia and Europe, broadening the reach and influence of the network while also providing partners access to global data sets.

As the Consumer Packaged Goods (CPG) industry’s largest open ecosystem of tech-driven solution providers, the NielsenIQ Connect Partner Network has continued on its growth trajectory by selectively adding innovative partners since its launch in 2016. Now, by entering new markets, the network will expand its value to both clients and partners across the globe.

“The NielsenIQ Connect Partner Network is not only core to the success and growth of Nielsen, but also to the CPG industry as a whole”, said Johan Sjostrand, Global President Retail Intelligence, NielsenIQ. “In addition to the network expanding into global markets, it is also continuously growing by way of the number of member companies, as we recently surpassed 100 partners. We are able to continuously attract powerful partners because we never stop evolving our ways of working with them, and the opportunities and benefits provided to them. The network is a win for our clients, our partners, and NielsenIQ overall, which makes the network so unique and leads us to believe its influence will only expand from here.”

Partners are provided with streamlined access to industry-leading data, enabling them to enhance their own solutions. The diversity of markets that Asia and Europe encompass will provide unique opportunities and benefits to the CPG industry as a whole.

In a recent survey conducted by the NielsenIQ Connect Partner Network team, 83% of partners responded that the network has helped them create a stronger, better offering for their clients, while over 90% of partners said they were able to identify new opportunities due to their membership. NielsenIQ clients also benefit a great deal, as they can work directly with any of our partners who specialize across a broad range of areas including demand planning, data harmonization, machine learning, and AI-driven promotion, to name a few. With the NielsenIQ Connect Partner Network, clients and partners work with a common dataset, enabling them to easily bridge insights and save time typically spent figuring out who to work with, how to get data to who they decide to work with, and how to make sense of disparate data sources.

“We are extremely excited about the global expansion of NielsenIQ’s Connect Partner Network and what this means for us and our clients'', said Satish Raman, Chief Strategy Officer, Fractal Analytics. “One of the things we love most about the network is its openness, enabling us to freely and easily collaborate with NielsenIQ, our clients and other Connected Partners in the network. The opportunity to scale that collaboration globally will open more avenues to enter new markets, expand our client base, increase the depth and breadth of our engagements, and drive our solution and product enhancements. This is a profound step forward for the network and big news for NielsenIQ, but I also see this as big news for Fractal and all other partners, because any enhancement to the network will ultimately add value to us and our clients.”

“We are very proud of the success, expansion, and continued growth of the Network”, said Brett Jones, SVP, Global Leader, NielsenIQ Connect Partner Network. “Making this network truly global is a major milestone for us. It has always been our goal to evolve in a variety of ways, whether that be through the addition of new partners, the enhancement of our offerings, or entering new markets like we are now with Asia and Europe. There are even bigger things ahead for the Connected Partner Network as we never stop exploring avenues to positively impact the CPG landscape.”

For additional information, or if you are interested in becoming a NielsenIQ Connect Partner Network member, please go to https://www.nielsen.com/us/en/solutions/capabilities/connected-partner-program/ . For a list of all partners please go to https://microsites.nielsen.com/connectedpartnernetwork/

ABOUT NIELSEN

Nielsen Holdings plc (NYSE: NLSN) is a global measurement and data analytics company that provides the most complete and trusted view available of consumers and markets worldwide. Nielsen is divided into two business units. Nielsen Global Media provides media and advertising industries with unbiased and reliable metrics that create a shared understanding of the industry required for markets to function. NielsenIQ (formerly known as Nielsen Global Connect) provides consumer packaged goods manufacturers and retailers with accurate, actionable information and insights and a complete picture of the complex and changing marketplace that companies need to innovate and grow.

Our approach marries proprietary Nielsen data with other data sources to help clients around the world understand what’s happening now, what’s happening next, and how to best act on this knowledge.

An S&P 500 company, Nielsen has operations in nearly 100 countries, covering more than 90% of the world’s population. For more information, visit www.nielsen.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye